GlassScriptPhysician profile
Allison Manley
NPI 1497305221
$19,801.37
in general payments reported to CMS, 2019-2025
34 companies · $4,799 in 2025
The $4,799 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2022: $2,672 · 2023: $4,956 · 2024: $7,147 · 2025: $4,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $800 · Education: $520 · Travel and Lodging: $89.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,493.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $800.00 |
| Education | $519.50 |
| Travel and Lodging | $89.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,861.64 | 2022-2025 | |
| Incyte Corporation | $2,338.86 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $2,227.14 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $1,903.06 | 2022-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,542.32 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $1,360.34 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $1,335.64 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $930.69 | 2022-2025 | |
| Ucb, INC. | $897.59 | 2022-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $831.84 | 2022-2025 | Ilumya, Winlevi |
| Pfizer INC. | $731.37 | 2022-2025 | |
| Organon LLC | $355.19 | 2025 | Vtama |
| Genzyme Corporation | $349.83 | 2022-2025 | |
| Leo Pharma INC. | $326.69 | 2022-2025 | Adbry, Anzupgo |
| Almirall LLC | $241.41 | 2022-2025 | Klisyri, Seysara |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $204.34 | 2022 | |
| Mayne Pharma Commercial LLC | $175.85 | 2023-2025 | |
| Amgen INC. | $134.63 | 2022-2025 | Otezla |
| Journey Medical Corporation | $133.64 | 2022 | |
| Novo Nordisk INC | $120.04 | 2021 | |
| Janssen Scientific Affairs, LLC | $106.94 | 2021 | |
| Galderma Laboratories, L.P. | $99.90 | 2023-2025 | Nemluvio, Epsolay, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.61 | 2023-2024 | Spevigo, Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $92.00 | 2023-2025 | Jublia, Cabtreo, Siliq |
| Arcutis Biotherapeutics, INC. | $90.60 | 2023-2025 | Zoryve |
| Fresenius Kabi USA, LLC | $75.92 | 2023-2024 | Idacio |
| Biofrontera INC. | $69.44 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Strata Skin Sciences, INC. | $48.30 | 2024-2025 | Xtrac |
| Sandoz INC. | $33.66 | 2023-2024 | Hyrimoz |
| Verrica Pharmaceuticals INC. | $23.40 | 2025 | Ycanth |
| Kyowa Kirin, INC. | $17.21 | 2023 | Poteligeo |
| Organogenesis INC. | $17.17 | 2025 | Puraply Wound Matrix |
| Helsinn Therapeutics (U.S.), INC. | $15.91 | 2025 | Valchlor |
| Merz North America, INC. | $13.20 | 2023 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Manley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.